Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma

Screening of proteins that specifically bound to the **RHOA(G17V)** mutant.





Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of nodal peripheral T-cell lymphoma, which has a poor prognosis and limited treatment options. This study showed that both RHOA(G17V) and VAV1 mutants intensify the T-cell receptor (TCR) pathway through accelerated phosphorylation of VAV1. Dasatinib, a multi-kinase inhibitor, efficiently blocked the VAV1 phosphorylation and the downstream TCR signaling. Based on this result, we are planning an investigator-initiated clinical trial of dasatinib.

References: M Fujisawa, M Sakata-Yanagimoto et al. Leukemia 32(3): 694-702, 2018.

Contact: Prof. S Chiba